Within the next 18 months, Novartis plans to seek regulatory approval for Proteus Biomedical's microchipped pills, which tracks medication adherence by time-stamping the patients ingestion of medications. Novartis global head of development Trevor Mundel told attendees at the recent Reuters Health Summit in New York that it will submit the smart pill system for regulatory approval in Europe...
